» Articles » PMID: 35068792

Prevalence, Predictors, and Outcomes of Esophageal Iasis in Cirrhosis: An Observational Study With Systematic Re and Meta-Analysis (CANDID-VIEW)

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2022 Jan 24
PMID 35068792
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gastrointestinal candidiasis is often neglected and potentially serious infection in cirrhosis patients. Therefore, we evaluated the prevalence, risk factors, and outcomes of esophageal candidiasis (EC) in cirrhotics and did a systematic review to summarize EC's available evidence in cirrhosis.

Methods: Consecutive patients with cirrhosis posted for esophagogastroduodenoscopy (EGD) at a tertiary care institute were screened for EC (cases) between January 2019 and March 2020. EC was diagnosed on EGD findings andor brush cytology. Controls (without EC) were recruited randomly, and EC's risk factors and outcomes were compared between cases and controls.Four electronic databases were searched for studies describing EC in cirrhosis. Prevalence estimates of EC were pooled on random-effects meta-analysis, and heterogeneity was assessed by I. A checklist for prevalence studies was used to evaluate the risk of bias in studies.

Results: EC was diagnosed in 100 of 2762 patients with cirrhosis (3.6%). Patients with EC had a higher model for end-stage liver disease (MELD) (12.4 vs. 11.2;  = 0.007), acute-on-chronic liver failure (ACLF) (26% vs. 10%;  = 0.003) and concomitant bacterial infections (24% vs. 7%;  = 0.001), as compared with controls. A multivariable model, including recent alcohol binge, hepatocellular carcinoma (HCC), upper gastrointestinal (UGI) bleed, ACLF, diabetes, and MELD, predicted EC's development in cirrhosis with excellent discrimination (C-index: 0.918). Six percent of cases developed the invasive disease and worsened with multiorgan failures, and four patients with EC died on follow-up.Of 236 articles identified, EC's pooled prevalence from 8 studies (all with low-risk of bias) was 2.1% (95% CI: 0.8-5.8). Risk factors and outcomes of EC in cirrhosis were not reported in the literature.

Conclusions: EC is not a rare infection in cirrhosis patients, and it may predispose to invasive candidiasis and untimely deaths. Alcohol binge, HCC, UGI bleed, ACLF, diabetes, and higher MELD are the independent predictors of EC in cirrhosis. At-risk patients with cirrhosis or those with deglutition symptoms should be rapidly screened and treated for EC.

Citing Articles

Fungal infections in liver cirrhosis.

Iqbal H, Mehmood B, Jones K, Sohal A, Roytman M Transl Gastroenterol Hepatol. 2024; 9:49.

PMID: 39091651 PMC: 11292070. DOI: 10.21037/tgh-24-6.


Predictors for oesophageal candidiasis in patients with liver cirrhosis.

Rajpurohit S, Musunuri B, Basthi Mohan P, Vani Lakshmi R, Bhat G, Shetty S Infez Med. 2023; 31(1):79-85.

PMID: 36908388 PMC: 9994834. DOI: 10.53854/liim-3101-11.


Fungal infections and the fungal microbiome in hepatobiliary disorders.

Hartmann P, Schnabl B J Hepatol. 2022; 78(4):836-851.

PMID: 36565724 PMC: 10033447. DOI: 10.1016/j.jhep.2022.12.006.

References
1.
Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang Y, Mookerjee R . Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care. 2012; 16(6):R227. PMC: 3672612. DOI: 10.1186/cc11882. View

2.
Mohamed A, Lu X, Mounmin F . Diagnosis and Treatment of Esophageal Candidiasis: Current Updates. Can J Gastroenterol Hepatol. 2019; 2019:3585136. PMC: 6854261. DOI: 10.1155/2019/3585136. View

3.
Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

4.
Nishimura S, Nagata N, Shimbo T, Asayama N, Akiyama J, Ohmagari N . Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy. PLoS One. 2013; 8(3):e58217. PMC: 3608638. DOI: 10.1371/journal.pone.0058217. View

5.
Bajaj J, OLeary J, Reddy K, Wong F, Olson J, Subramanian R . Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012; 56(6):2328-35. PMC: 3492528. DOI: 10.1002/hep.25947. View